References
- Meng X Dizon DS Yang S et al. Strategies for molecularly enhanced chemotherapy to achieve synthetic lethality in endometrial tumors with mutant p53 . Obstet. Gynecol. Int. 2013 , 828165 ( 2013 ).
- Meng X Laidler LL Kosmacek EA et al. Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53 . Gynecol. Oncol.128 ( 3 ), 461 – 469 ( 2013 ).
- Reck M Kaiser R Mellemgaard A et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a Phase III, double-blind, randomised controlled trial . Lancet Oncol.15 ( 2 ), 143 – 155 ( 2014 ).
- du Bois A Kristensen G Ray-Coquard I et al. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled Phase III trial . Lancet Oncol.17 ( 1 ), 78 – 89 ( 2016 ).
- Fang RH Hu C-MJM Luk BT et al. Cancer cell membrane-coated nanoparticles for anti-cancer vaccination and drug delivery . Nano Lett.14 ( 4 ), 2181 – 2188 ( 2014 ).